Annual Cash & Cash Equivalents
$70.97 M
-$139.55 M-66.29%
December 31, 2023
Summary
- As of February 7, 2025, SPRY annual cash & cash equivalents is $70.97 million, with the most recent change of -$139.55 million (-66.29%) on December 31, 2023.
- During the last 3 years, SPRY annual cash & cash equivalents has risen by +$46.45 million (+189.43%).
- SPRY annual cash & cash equivalents is now -66.29% below its all-time high of $210.52 million, reached on December 31, 2022.
Performance
SPRY Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$39.66 M
+$3.03 M+8.28%
September 30, 2024
Summary
- As of February 7, 2025, SPRY quarterly cash and cash equivalents is $39.66 million, with the most recent change of +$3.03 million (+8.28%) on September 30, 2024.
- Over the past year, SPRY quarterly cash and cash equivalents has increased by +$3.03 million (+8.28%).
- SPRY quarterly cash and cash equivalents is now -81.16% below its all-time high of $210.52 million, reached on December 31, 2022.
Performance
SPRY Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SPRY Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -66.3% | +8.3% |
| 3 y3 years | +189.4% | +8.3% |
| 5 y5 years | +189.4% | +8.3% |
SPRY Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -66.3% | +18.2% | -81.2% | +8.3% |
| 5 y | 5-year | -66.3% | +189.4% | -81.2% | +8.3% |
| alltime | all time | -66.3% | +189.4% | -81.2% | +8.3% |
ARS Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $39.66 M(+8.3%) |
| Jun 2024 | - | $36.63 M(-34.6%) |
| Mar 2024 | - | $56.01 M(-21.1%) |
| Dec 2023 | $70.97 M | $70.97 M(+17.2%) |
| Sep 2023 | - | $60.53 M(-49.1%) |
| Jun 2023 | - | $119.02 M(+35.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $87.86 M(-58.3%) |
| Dec 2022 | $210.52 M(+250.5%) | $210.52 M(+372.1%) |
| Jun 2022 | - | $44.59 M(-25.8%) |
| Dec 2021 | $60.06 M(+144.9%) | - |
| Dec 2021 | - | $60.06 M |
| Dec 2020 | $24.52 M | - |
FAQ
- What is ARS Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is ARS Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is ARS Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of SPRY is $70.97 M
What is the all time high annual cash & cash equivalents for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high annual cash & cash equivalents is $210.52 M
What is ARS Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, SPRY annual cash & cash equivalents has changed by -$139.55 M (-66.29%)
What is ARS Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SPRY is $39.66 M
What is the all time high quarterly cash and cash equivalents for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high quarterly cash and cash equivalents is $210.52 M
What is ARS Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, SPRY quarterly cash and cash equivalents has changed by +$3.03 M (+8.28%)